Compare SFL & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFL | OCUL |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2004 | 2014 |
| Metric | SFL | OCUL |
|---|---|---|
| Price | $12.47 | $10.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $12.00 | ★ $23.56 |
| AVG Volume (30 Days) | 1.2M | ★ 2.6M |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | ★ 7.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,990,000.00 |
| Revenue This Year | N/A | $7.93 |
| Revenue Next Year | $13.07 | $96.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.48 |
| 52 Week Low | $6.73 | $6.23 |
| 52 Week High | $12.94 | $16.44 |
| Indicator | SFL | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 59.01 | 60.22 |
| Support Level | $11.89 | $7.96 |
| Resistance Level | $12.86 | $11.62 |
| Average True Range (ATR) | 0.31 | 0.49 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 65.19 | 58.50 |
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities. The company operates as a single reportable segment, generating revenue from long-term, fixed-rate charters. Its Additional revenue sources include sales-type lease interest income, voyage charter and pool revenues, and drilling contract revenues.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.